Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI. Cooper TM, et al. Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25. Cancer. 2014. PMID: 24771494 Free PMC article. Clinical Trial.
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA. Tarlock K, et al. Among authors: cooper t. Pediatr Blood Cancer. 2015 Jun;62(6):1048-54. doi: 10.1002/pbc.25437. Epub 2015 Feb 8. Pediatr Blood Cancer. 2015. PMID: 25662999
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. Cooper TM, et al. Pediatr Blood Cancer. 2017 Aug;64(8):10.1002/pbc.26414. doi: 10.1002/pbc.26414. Epub 2017 Apr 14. Pediatr Blood Cancer. 2017. PMID: 28409853 Free PMC article. Clinical Trial.
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.
Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K. Pikman Y, et al. Among authors: cooper tm. Cancer Discov. 2021 Jun;11(6):1424-1439. doi: 10.1158/2159-8290.CD-20-0564. Epub 2021 Feb 9. Cancer Discov. 2021. PMID: 33563661 Free PMC article. Clinical Trial.
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. Tarlock K, et al. Blood. 2021 Sep 30;138(13):1137-1147. doi: 10.1182/blood.2020009652. Blood. 2021. PMID: 33951732 Free PMC article. Clinical Trial.
Targeted Therapy in Pediatric AML: An Evolving Landscape.
Jones LM, Tarlock K, Cooper T. Jones LM, et al. Among authors: cooper t. Paediatr Drugs. 2021 Sep;23(5):485-497. doi: 10.1007/s40272-021-00467-x. Epub 2021 Aug 22. Paediatr Drugs. 2021. PMID: 34420195 Review.
2,384 results